Radar

Radar

The field read on diabetes. A fast weekly brief — the editorial read, with every source numbered and graded by where its evidence comes from — and a deeper monthly report across six source-worlds.

Weekly brief

A fast read of the week across the field — the editorial take up top, every source numbered below. A new brief each week.

27 Week 27 · 2026 From Insulin Management to Disease Modification — Pediatric T1D's Turning Point FDA's pediatric teplizumab approval and the first OTC CGM for children signal a structural shift in type 1 diabetes care — while generic tirzepatide and metabolic mechanism research reshape the broader field. Read the brief → 26 Week 26 · 2026 The Oral and Next-Gen Incretin Field Goes Wide Registrations push incretin biology into new oral agents, new comparators, and indications well beyond glycemia. Read the brief →
Monthly report

The monthly flagship — six source-worlds synthesized into one read.

Jun Monthly · No. 1 · June 2026 Radar · Diabetes — June 2026 The monthly read across the field: six source-worlds — literature, trials, industry, consulting, policy, commentary — graded by where the evidence comes from. Open the issue →

A question worth thinking through together?

For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.

Request a confidential scoping call

Prefer email? contact@integralbiostrategy.com